March had been a particularly good time for the Brooklyn Immuno Therapeutics (NYSE: BTX) stock as it rallied quite strongly.
Recently, the stock had also hit its highest level in 52 weeks but since then it has slumped quite sharply and gone down by 60% so far. There has been no development with regards to Brooklyn Immuno so far this week but last week the company had made a significant announcement. Last week the company announced its new Chief Executive Officer. However, that was not the only reason why the stock was in play in the markets. The company, which is involved in the development of immunotherapies for treating cancer, has some highly anticipated trials in the works.
In addition to that, investors also need to note that the company has found a niche in the market, neck and head cancers, in which it believes it could grow. Hence, despite the recent fall, investors could consider keeping the Brooklyn Immuno Therapeutics stock on their watch lists.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.